# Study of Therapeutic Options for Subjects Discontinuing Efalizumab and Experiencing Disease Recurrence

> **NCT01079988** · PHASE4 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 41 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Cyclosporins
- **DRUG:** Retinoids
- **DRUG:** Systemic corticosteroids
- **DRUG:** Methotrexate
- **DRUG:** Systemic corticosteroids/methotrexate

## Key facts

- **NCT ID:** NCT01079988
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02
- **Primary completion:** 2004-12
- **Final completion:** 2005-04
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2014-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01079988

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01079988, "Study of Therapeutic Options for Subjects Discontinuing Efalizumab and Experiencing Disease Recurrence". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01079988. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*